Total Payments
$6,694
2024 Payments
$2,076
Companies
32
Transactions
389
Medicare Patients
1,435
Medicare Billing
$133,574
Payment Breakdown by Category
Food & Beverage$6,687 (99.9%)
Education$7.33 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,687 | 388 | 99.9% |
| Education | $7.33 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,636 | 93 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $873.34 | 64 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $504.56 | 24 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $497.08 | 18 | $0 (2024) |
| GENZYME CORPORATION | $449.38 | 17 | $0 (2024) |
| Janssen Biotech, Inc. | $335.84 | 20 | $0 (2024) |
| Gilead Sciences, Inc. | $312.49 | 22 | $0 (2024) |
| Celgene Corporation | $225.87 | 15 | $0 (2024) |
| QOL Medical, LLC | $224.92 | 14 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $205.87 | 20 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,076 | 102 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($402.18) |
| 2023 | $1,584 | 82 | ABBVIE INC. ($353.96) |
| 2022 | $20.92 | 1 | Lucid Diagnostics Inc. ($20.92) |
| 2021 | $51.33 | 3 | AbbVie Inc. ($33.06) |
| 2020 | $230.44 | 12 | AbbVie Inc. ($84.38) |
| 2019 | $746.75 | 42 | AbbVie, Inc. ($325.82) |
| 2018 | $803.65 | 58 | AbbVie, Inc. ($227.58) |
| 2017 | $1,181 | 89 | AbbVie, Inc. ($329.00) |
All Payment Transactions
389 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/17/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $14.75 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/16/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: VIROLOGY | ||||||
| 12/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $12.95 | General |
| Category: Gastroenterology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.28 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/26/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: Gastroenterology | ||||||
| 11/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $16.74 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/15/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $25.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Immunology | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: Immunology | ||||||
| 11/05/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $7.12 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Gastroenterology | ||||||
| 11/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Gastroenterology | ||||||
| 10/29/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $21.55 | General |
| Category: THERAPY FOR CSID | ||||||
| 10/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/25/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: Gastroenterology | ||||||
| 10/08/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $25.27 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.97 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $23.15 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/26/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 323 | 330 | $110,059 | $31,547 |
| 2022 | 8 | 308 | 311 | $106,072 | $32,163 |
| 2021 | 10 | 445 | 462 | $136,620 | $44,083 |
| 2020 | 9 | 359 | 380 | $89,080 | $25,781 |
Total Patients
1,435
Total Services
1,483
Medicare Billing
$133,574
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 47 | 47 | $24,722 | $9,409 | 38.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 76 | 76 | $31,616 | $7,299 | 23.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 56 | 56 | $19,600 | $3,675 | 18.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 47 | 47 | $14,100 | $3,402 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 42 | $6,090 | $2,461 | 40.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 25 | $5,375 | $2,460 | 45.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $5,576 | $2,059 | 36.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 20 | 20 | $2,980 | $782.32 | 26.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 48 | 48 | $25,248 | $9,311 | 36.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 82 | 82 | $34,112 | $8,339 | 24.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 47 | 47 | $16,450 | $3,170 | 19.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 16 | 16 | $6,112 | $2,789 | 45.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 33 | $7,095 | $2,745 | 38.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 30 | 30 | $9,000 | $2,535 | 28.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 35 | $5,075 | $2,312 | 45.6% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 20 | 20 | $2,980 | $961.69 | 32.3% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 89 | 89 | $37,024 | $9,314 | 25.2% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 43 | 43 | $22,618 | $8,647 | 38.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 62 | $13,330 | $6,046 | 45.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 50 | 50 | $16,400 | $5,980 | 36.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 51 | 58 | $8,410 | $3,610 | 42.9% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 48 | 48 | $14,400 | $3,395 | 23.6% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 42 | 43 | $15,050 | $2,795 | 18.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 13 | 13 | $4,966 | $2,384 | 48.0% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 19 | 19 | $2,831 | $1,089 | 38.5% |
About Dr. Patrick Lam, DO
Dr. Patrick Lam, DO is a Gastroenterology healthcare provider based in Goodyear, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1326095613.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Lam, DO has received a total of $6,694 in payments from pharmaceutical and medical device companies, with $2,076 received in 2024. These payments were reported across 389 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($6,687).
As a Medicare-enrolled provider, Lam has provided services to 1,435 Medicare beneficiaries, totaling 1,483 services with total Medicare billing of $133,574. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Goodyear, AZ
- Active Since 05/30/2006
- Last Updated 11/18/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1326095613
Products in Payments
- DUPIXENT (Biological) $946.46
- TRULANCE (Drug) $477.11
- Humira (Biological) $362.86
- XIFAXAN (Drug) $266.87
- ENTYVIO (Biological) $256.37
- Creon (Drug) $234.19
- ZEPOSIA (Drug) $225.87
- Mavyret (Drug) $197.94
- STELARA (Biological) $196.63
- RINVOQ (Biological) $192.87
- SKYRIZI (Biological) $188.38
- Trulance (Drug) $157.17
- Sucraid (Drug) $141.82
- VIBERZI (Drug) $134.82
- LINZESS (Drug) $129.00
- MAVYRET (Drug) $124.58
- ZEPATIER (Drug) $120.01
- APRISO (Drug) $107.29
- Entyvio (Biological) $100.08
- RELISTOR ORAL (Drug) $96.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.